Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy

BACKGROUND: The current therapeutic antibodies and chimeric antigen receptor (CAR) T cells are capable of recognizing surface antigens, but not of intracellular proteins, thus limiting the target coverage for drug development. To mimic the feature of T-cell receptor (TCR) that recognizes the complex...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xin, Xu, Yixiang, Xiong, Wei, Yin, Bingnan, Huang, Yuqian, Chu, Junjun, Xing, Changsheng, Qian, Chen, Du, Yang, Duan, Tianhao, Wang, Helen Y, Zhang, Ningyan, Yu, John S., An, Zhiqiang, Wang, Rongfu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8961179/
https://www.ncbi.nlm.nih.gov/pubmed/35338087
http://dx.doi.org/10.1136/jitc-2021-004035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8961179/
https://www.ncbi.nlm.nih.gov/pubmed/35338087
http://dx.doi.org/10.1136/jitc-2021-004035

Ejemplares similares